Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week?  InvestorsObserver
Read the original here:
Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver
England is in crisis. They lost a beloved figurehead this month but for decades prior were losing scientific ground. If you look for the home of the modern organic food and anti-vaccine movements, you find their nexus in 1990s England.
The primary royal behind those beliefs is now King Charles III.
In order to manage the $28 billion he inherits (tax-free, paying taxes only applies to peasants in England)(1) he will have to give his $1.5 billion estate to his son, the new Prince of Wales, William (also tax free) but the Prince is not only taking over during a time when Brits are wondering why they still care about a throne that hasnt been relevant in hundreds of years, he is taking over at a time when being anti-science is no longer fashionable for progressive elites.
Though it was recently the darling of the intelligentsia, and Prince Charles longed to belong in that circle, anti-vaccine sentiments have become proletariat since COVID-19. The war on science when it comes to food harms a lot more people worldwide each year than the pandemic did. Hundreds of thousands of kids could stop going blind each year with Golden Rice but elites like King Charles III give money to groups that block its implementation.
Prince William could start to gain back some credibility for the family by jettisoning the organic food fetish of his father. Organic food, like the anti-vaccine movement, is a relic of 1990s England. Dr. Andrew Wakefield set off the modern anti-vaccine craze the same way that English environmental activists set off the Frankenfood one. Now supplements, wellness, and organic are all giant businesses based on exploitation of famous names who wanted to impress their elite friends
The world should have passed the anti-vaccine and anti-food movement by but they persist in large part because of the new British monarch and his quasi-American royalty of American Democrats counterpart, Robert F. Kennedy, Jr.(2)
Its easy to embrace science, especially in light of their history making changes when it was needed. They changed their name to Windsor from Saxe-Coburg and Gotha during World War I to help commoners forget the British royal family is German during a time that Germany was shooting at English men in Europe. Given that public relations success, they can certainly change their tune when it comes to science.
Perhaps due to an infusion of new blood outside the shockingly limited pool drawn from during the 19th and 20th centuries, Prince William seems to be a more genetically gifted thinker than his father. He can show it by embracing the modern world, where food and medicine are embraced.(3)
He doesnt actually have to divest from the farm, that is just me getting attention in a title. It is enough if he acknowledges that having peasants toil for his carrots only using specially labeled toxic pesticides is a pastime for the rich, and not a way to feed the world.
(1) The same way California Governor Gavin Newsom doesnt want people who make over $2 million each year to pay higher taxes to subsidize the electric cars the Governor insists Uber drivers need to buy. High taxes are for the middle class and the poor, not the donors he will need in order to fail running for President in 2024.
(2) Nothing looks more hypocritical than people on the left in England and the US suddenly endorsing vaccines when just two years ago they opposed them. It instead reeks of politics, and politics need to be a no-no for the new generation of British royals, lest they be relegated to the name recognition of the Queen of the Netherlands, whoever that is.
(3) and not just engage in publicity stunts about energy costs that are squarely the blame of the government his father now seeks to lead.
Hank Campbell founded Science 2.0 in 2006, and writes for USA Today, Wall Street Journal, CNN, and more. His first book,Science Left Behind,was the #1 bestseller on Amazon for environmental policy books. Follow Hank on Twitter@HankCampbell
A version of this article was originally posted atScience 2.0and is reposted here with permission. Science 2.0 can be found on Twitter@science2_0
DUBLIN--(BUSINESS WIRE)--The "Biotechnology Market Research Report by Technology (Cell-based Assays, Chromatography, and DNA Sequencing), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Biotechnology Market size was estimated at USD 876.74 billion in 2021, USD 1,023.15 billion in 2022, and is projected to grow at a CAGR 16.87% to reach USD 2,234.84 billion by 2027.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biotechnology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biotechnology Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biotechnology Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biotechnology Market?
4. What is the competitive strategic window for opportunities in the Global Biotechnology Market?
5. What are the technology trends and regulatory frameworks in the Global Biotechnology Market?
6. What is the market share of the leading vendors in the Global Biotechnology Market?
7. What modes and strategic moves are considered suitable for entering the Global Biotechnology Market?
Market Dynamics
Drivers
Restraints
Opportunities
Challenges
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/ijpdlj
See the rest here:
The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 - ResearchAndMarkets.com - Business Wire
With significant investments being made into biotechnology and research and development (R&D), life science organizations are becoming increasingly profitable targets for cybercriminals. Tremendous strides are being made in terms of scientific discoveries and companies must also keep pace by managing security risks and protecting scientific data.
One cybersecurity report found that ransomware attacks a form of malware that locks users out of their devices or files until a ransom is paid increased by 485% in 2020 compared to 2019, likely influenced by the COVID-19 pandemic. Additionally, another report found that the average total cost of a data breach in the pharmaceutical industry was $5.06 million.
In light of these rising cybersecurity risks and the threats they pose, Technology Networks spoke to Zach Powers, chief information security officer at Benchling, an R&D cloud platform for the biotechnology industry. We discuss why the biotechnology industry is being targeted by cybercriminals, the importance of data security and how the industry can mitigate these threats.
Sarah Whelan (SW): Can you explain what the Benchling R&D Cloud is, and how it is designed to advance scientific research and development? How can this benefit small academic laboratories through to large-scale biotechnology companies?
Zach Powers (ZP): Benchling was started with a vision of making research and development what its meant to be a collaborative process to turn ideas into scientific progress. In the past few years with the pandemic, this vision has felt more urgent and important than ever. Now, more than 200,000 scientists use Benchlings R&D Cloud as a central source of truth for biotech R&D to centralize data, improve collaboration and access insights, ultimately accelerating the path to discovery.
Looking to examples of how our R&D Cloud facilitates progress in the scientific community we helped Syngenta go from data silos to data as an advantage, now with a data infrastructure that serves 90 locations across different languages, regulations and time zones in their mission to build crops that require fewer inputs while producing great outputs. Using Benchling, Syngenta reported a 72% improvement in sharing data across geos and a large team.
SW: What considerations need to be made in terms of data security for these types of cloud-based platforms?
ZP: Biotech organizations generate revenue based on intellectual property, and if compromised, a great deal of revenue stands to be lost. These organizations are also highly regulated due to the potential human impact of their products and complying with regulations can make or break the organizations ability to compete.
Both of these factors mean that for a cloud-based platform like Benchling, maintaining industry-leading security, privacy and compliance standards for biotech customers is paramount. Enterprise software as a service (SaaS) companies have a responsibility to develop cloud software and infrastructure securely. To do this, they use automated vulnerability management, routine penetration testing, asset management, configuration management, threat detection and response engineering, etc. The end result is that many cloud software products undergo more security scrutiny, on a more frequent basis, than on-premises technologies do. Not all cloud products are the same when it comes to security, but it is becoming increasingly common for enterprise SaaS companies to approach security in this way. When evaluating cloud platforms, customers should evaluate how much an enterprise SaaS company invests in security on an ongoing basis; is there an economy of scale on security that the customer can benefit from?
SW: How important is data security and governance to the industry, and how has this changed over the years as new discoveries are made and biotechnology becomes a more lucrative target for cybercriminals?
ZP: In recent years, threat actors have become more advanced and are highly funded, educated and organized businesses. Whats more, the most dangerous threat actors are being employed by adversaries of the USA and European Union. These organizations are in business to make profits, and many even have revenue targets. They aim to gain illegal access to some of the worlds most sensitive intellectual property for financial gain.
Pharmaceutical companies are now routinely targeted and attacked by these advanced threat actors, and in 2021 almost all (98%) of pharmaceutical companies experienced at least one security intrusion. In fact, over 20% of businesses have lost business-critical data or intellectual property in the last year alone.
It is clear that robust data security and governance are more important than ever, especially as the biotechnology industry continues to increase in value with the influx of valuable data it generates.
SW: What lessons do you think life sciences and biotechnology institutions can take from other industries regarding managing security risks?
ZP: Managing security risks appropriately today requires engineering, automation, real-time analytics, threat intelligence, significant tooling etc. It also takes a strategy of applying security throughout an organization, with multiple layers of defense, points of detection and built-in response options. This level of investment can seem daunting, but against adversaries who are well funded and are singularly focused on their targets, doing less only makes it easier for a threat actor to accomplish their goals. In the security industry, we often talk about the cost to the attacker and how appropriately investing in security can raise the cost sufficiently to either deter an attacker or slow down their attacks sufficiently for detection mechanisms to trigger and response plans to be executed. Threat actors consider the cost to carry out an attack; it is a business after all. Biotech institutions have the ability to influence that cost model.
When evaluating whether to invest in security at this level, many life sciences and biotech institutions have sticker shock as the cost of security is rising rapidly year over year. The advice I give biotech institutions is to look at how many other industries have taken advantage of the economies of scale that mature cloud computing companies can offer on security, resiliency, disaster response and more. If a biotech institution is not ready to invest materially in security themselves, building out the type of world-class security program and capabilities necessary to protect data today, then they can still get secure outcomes by moving their data and workflows into cloud platforms that have invested materially in security. More times than not, mature cloud platforms have invested orders of magnitude more in security than their customers do and continue to on an ongoing basis. No security strategy is perfect, but a strategy that takes advantage of the economies of scale on security that mature cloud platforms provide tends to fare far better than not.
There is another fundamental benefit to approaching security in this way. The adoption of a cloud-first strategy can significantly increase a biotech institutions data liquidity. Cloud architectures excel at enabling data to be found, to be accessed by those who need it, be interoperable between disparate systems and to be reusable. These are known as the FAIR data principles. It is a key focus for biotech institutions today, which have struggled with data residing in disparate, on-premises silos for years.
We can again draw lessons from many other industries, looking at how they evolved and profited from greater data liquidity. For example, enterprise SaaS, banking and healthcare each came to view cloud computing and more modern security as keys to unlocking data liquidity, supporting rapid growth and unparalleled innovation. If data liquidity is the destination, then the easiest road to take is via cloud computing and data platforms. Cloud computing and data platforms bring consistency in data modeling, easily allow for programmatic interfaces, allow for easier governance and security assurance and allow people to find, access and use data readily.
SW: What changes do you think are needed in the future to ensure data security as science advances? What are the biggest challenges that need to be addressed?
ZP: One of the biggest challenges I see is a distrust in cloud technology, which is, unfortunately, a more common sentiment in biotech, particularly in Europe. A lot of biotech institutions are still adhering to a security strategy from the late 1990s, using on-premises technology and essentially using firewalls as the first and only line of defense. More times than not, maintaining an on-premises strategy exposes you to more risk because 100% of the security responsibility and resourcing is on you. Most companies that distrust cloud computing are actually less secure than the cloud providers they distrust.
There are many myths about whether or not cloud computing is secure and its important to separate fact from fiction. When we look at breach statistics, nothing in the data says that on-premises technologies are more secure. But beyond taking a data-driven approach to making security decisions, the most important lens I can offer to change attitudes around the security of cloud computing is that of economies of scale. Companies that adopt cloud and enterprise SaaS take advantage of economies of scale on security that modern software companies provide. Enterprise SaaS companies have a responsibility for security, and they have security capabilities and teams beyond what most companies can afford.
Its the same with Benchling, security is an integral part of the product were offering to our customers. To this aim, we invest far more in security than most customers can afford to, and we have an abundance of expertise. Benchling embeds security engineering into our software development lifecycle and cloud infrastructure operations. Vulnerability testing happens daily, all code checked into production undergoes security testing and any security issues found are fixed within industry-leading service level agreements.
Biotech institutions can get a more secure outcome by taking advantage of cloud software and platforms. We take care of the hard stuff in security so that our customers can focus on advancing science and delivering humanity-impacting products.
Zach Powers was speaking to Sarah Whelan, Science Writer for Technology Networks.
See the rest here:
Tackling Cybersecurity Threats in the Biotechnology Industry - Technology Networks
The Global Tribulus Terrestris Extract Market study report consists the data about overall revenue & sales during the forecast period of 2022 to 2028. The objective of MarketQuest.biz is to offer a complete picture of the market to the customers and assist them in creating increased techniques. The potential growth likelihoods along with the penetration rate analysis of the Tribulus Terrestris Extract market are included in the report to understand the adoption rate and formulate strategies likewise.
The report also provides a comprehensive picture of the Tribulus Terrestris Extract market by synthesizing, summating, and studying data from various sources by examining key parameters like promotions, profit, pricing, and competition. The market estimates have been evaluated by considering the effect of different social, political, economic, legal, and technological factors, based on extensive primary research, secondary research, and in-house databases.
DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/103606
Moreover, the markets total volume of sales and marketing, the overall amount of production & consumption, in-depth price analysis, profit margins, export, import, vendor landscapes, competitive landscape analysis, and key factors for accurate market appraisal are all well-combined. The report provides a year-to-year growth of the market for the user to be primarily aware of the changing scenario of the global Tribulus Terrestris Extract market.
Some of the most promising players include:
Based on product type, global Tribulus Terrestris Extract market research report:
On the basis of the applications, Tribulus Terrestris Extract market research report:
ACCESS FULL REPORT: https://www.marketquest.biz/report/103606/global-tribulus-terrestris-extract-market-2022-by-manufacturers-regions-type-and-application-forecast-to-2028
The study by geography highlights the consumption of the product/service in the region and indicates the factors affecting Tribulus Terrestris Extract market within each region:
Read this article:
Tribulus Terrestris Extract Market Demand With Future Forecast Green Labs, BioTae, Nutra Green Biotechnology, JIAHERB The Colby Echo News - The...
China has very small farms; there hasnt been a lot of infrastructure put in place in terms of knowledge or solid assets. Now Syngenta is enabling them with agronomists and digital infrastructure.
When it comes to Beijings technological ambitions, high profile hardware like semiconductors and electric vehicles tend to dominate global headlines. But in China, where almost 20 percent of the global population lives on 8.5 percent of the worlds arable land, finding innovative ways to reap more food from every hectare of seeds sown has long been one of the governments highest priorities.
Chinese agriculture and food demand is in inherent conflict, says Wendong Zhang, an assistant professor at Cornell Universitys Dyson School of Applied Economics and Management and a specialist in Chinas agricultural development. China wont be able to have more land. They wont be able to have better quality soil. The thing they can control is technology.
Beijings realization that technology would be key to increasing its food self-sufficiency is what made Syngenta such a valuable target for ChemChina. Syngenta, after all, is the world-leader in crop protection products and globally the number three producer of seeds, including selectively-bred hybrids and genetically modified seeds. Alongside rivals like Germanys Bayer and Americas Corteva (formerly DowDupont), the company is pushing the boundaries of seed genomics using CRISPR-Cas9, a tool that allows researchers to tweak the genetics of living organisms.
Emboldened by its ownership of Syngenta, China seems to be crossing the rubicon when it comes to high-tech agriculture. Officials are now calling cutting-edge seeds agriculture microchips, according to Chinese state media.
And safety approvals for GM seeds appear to be speeding up: in early 2022, Beijings Ministry of Agriculture and Rural Affairs (MARA) granted safety certificates to three Syngenta GM corn seeds as well as a seed from the domestic firm Hangzhou Ruifeng Bio-Tech Company and several others from Chinese universities. In June, MARA also released guidelines, for the first time, that could pave the way for companies to begin commercial planting of GM products.
And with its high-profile Shanghai listing, Syngenta might help the Chinese government out of a dilemma of its own making: convincing the general public that GMOs are safe. At the very least, the company cant be viewed as a trojan horse for U.S. bioweapons. Syngentas MAP program has even introduced QR codes on food packaging so consumers can scan their food and see a photo of the Chinese farmer who grew it.
To help itself out of its GMO bind, Beijing is also positioning its efforts in direct gene editing as a kind of technological leapfrogging these newer engineering methods do not require the introduction of foreign DNA, unlike todays genetic modification, in which bacteria from one organism is transplanted into another ( la the Bt genes added into the corn genome). As [Shane] Thomas, the analyst, notes, the industry as a whole is moving towards this more precise kind of genetic tweaking.
This is an excerpt. Read the original post here
The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 5% during intraday trading today. Investors are responding positively to Vir Biotechnology announcing new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. And the data was presented in one oral and two poster presentations at the International Liver Congress (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).
In summary, the data presented at ILC demonstrated that a six-dose regimen of VIR-2218 provided greater and more durable reductions in hepatitis B surface antigen (HBsAg) than a two-dose regimen, with all participants achieving a >1 log10 IU/mL reduction during the trial. Phase 1 results evaluating VIR-3434 showed that a single dose (6 mg, 18 mg, 75 mg or 300 mg) resulted in a rapid reduction of HBsAg, with the largest and most durable response noted with the 300 mg dose. Finally, preclinical in vivo data demonstrated that the combination of both investigational compounds resulted in greater HBsAg reductions than either compound alone.
As part of its ongoing efforts to advance its broad HBV portfolio, Vir is expecting to dose the first patient in Part B of the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 in combination with VIR-3434 for 24 and 48 weeks, and in combination with interferon, by the end of June. And previously reported results from Part A demonstrated that VIR-3434 combined with VIR-2218 provided an additional 2 log decline in HBsAg loss over the 3 log decrease with VIR-2218 alone. No drug-related safety signals were observed. The additional data from Part A are expected later this year. However, with clinical trial sites in Ukraine and Moldova, the Company is continuing to monitor the war in Ukraine for any potential impact on timing.
The additional milestones expected in the second half of 2022 include:
Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-.
Initial data from the Phase 2 trial led by Brii Biosciences evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection.
The initiation of a Phase 2 platform trial of VIR-2218 in combination with VIR-3434 in viremic patients (THRIVE/STRIVE sub-protocols), with initial data expected in the second half of 2023.
The initiation of a Phase 2 trial of VIR-2218 in combination with VIR-3434 for the treatment of chronic hepatitis D virus (HDV) infection, with initial data expected in 2023.
The company also expects to report initial data from the Phase 2 trial evaluating various combinations of VIR-2218, selgantolimod (GS-9688), Gilead Sciences investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor, as a potential cure regimen for chronic HBV infection in the first half of 2023.
KEY QUOTE:
The data presented at the International Liver Congress 2022 continue to indicate that our therapeutic strategy of combining an antiviral with an immunomodulator to restore immunologic control in patients with chronic HBV is additive and offers the potential for a functional cure. As we continue to evaluate VIR-2218 and VIR-3434, we are encouraged by the potential of these two investigational medicines alone and in combination. These data, alongside the anticipated initiation of Part B of the MARCH trial by the end of June, are important milestones in our broad HBV portfolio for which we expect multiple data readouts throughout 2022 and 2023.
Carey Hwang, M.D., Ph.D., Virs senior vice president, clinical research, head of chronic infection
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
See more here:
Vir Biotechnology (VIR) Stock: Why It Increased Over 5% Today - Pulse 2.0
Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE Get Rating) by 30.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,134 shares of the biotechnology companys stock after acquiring an additional 1,657 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbanks holdings in Cerevel Therapeutics were worth $250,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of CERE. Candriam Luxembourg S.C.A. bought a new stake in Cerevel Therapeutics during the 4th quarter valued at $3,424,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Cerevel Therapeutics by 24.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 310,000 shares of the biotechnology companys stock valued at $10,050,000 after purchasing an additional 60,000 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Cerevel Therapeutics by 105.8% during the 4th quarter. First Trust Advisors LP now owns 107,026 shares of the biotechnology companys stock valued at $3,470,000 after purchasing an additional 55,029 shares during the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of Cerevel Therapeutics by 65.1% during the 4th quarter. Rafferty Asset Management LLC now owns 135,197 shares of the biotechnology companys stock valued at $4,383,000 after purchasing an additional 53,303 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in shares of Cerevel Therapeutics by 21.5% during the 4th quarter. Woodline Partners LP now owns 237,326 shares of the biotechnology companys stock valued at $7,694,000 after purchasing an additional 41,995 shares during the last quarter.
Several brokerages have recently commented on CERE. The Goldman Sachs Group decreased their price objective on Cerevel Therapeutics from $28.00 to $20.00 and set a neutral rating for the company in a report on Tuesday, May 24th. Mizuho assumed coverage on Cerevel Therapeutics in a research note on Wednesday, July 6th. They issued a neutral rating and a $30.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Cerevel Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $39.43.
Shares of CERE stock opened at $26.97 on Friday. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -15.77 and a beta of 2.44. The business has a fifty day moving average of $26.18 and a 200 day moving average of $28.77. Cerevel Therapeutics Holdings, Inc. has a 1 year low of $19.86 and a 1 year high of $46.16.
Cerevel Therapeutics (NASDAQ:CERE Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts consensus estimates of ($0.44) by ($0.02). During the same quarter last year, the firm posted ($0.40) earnings per share. As a group, equities research analysts expect that Cerevel Therapeutics Holdings, Inc. will post -1.94 earnings per share for the current year.
(Get Rating)
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
See the rest here:
Zurcher Kantonalbank Zurich Cantonalbank Buys 1657 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - Defense World
ISLAMABAD Three-day Pakistan-Turkey-Kazakhstan Youth Forum on Biotechnology will be arranged in the month of September with an emphasis on increasing the share of Muslim countries in the biotechnology global market.
The forum, to be held from September 13-15, is being sponsored by COMSTECH-the OIC Standing Committee for Scientific and Technological Cooperation, Islamic Organization for Food Security (IOFS) and Islamic Cooperation Youth Forum (ICYF), an official of COMSTECH told APP.
The academics, students and researchers from the OIC countries are likely to participate in the forum.
The global biotechnology market is anticipated to reach a market value of US$ 775 billion by 2024 with an annual growth rate of 7.7%.
Increased spending on biotechnology research and development, favourable initiatives by governments, global food security and the increasing need for emerging technologies are some of the factors influencing this growth.
Unfortunately, the share of Muslim countries in this global market of biotechnology is very small and needs to be increased.
This proposed tripartite youth forum (Pakistan-Turkey-Kazakhstan) will help promote excellence and competence in the field of agricultural biotechnology among Muslim countries. The theme of the forum Agriculture Biotechnology aims at providing the best knowledge and resources to young participants to advance their research goals, the official informed.
The youth forum will stimulate the desire to collaborate and change the world of agricultural biotechnology and innovation by promoting state-of-the-art practices in biotechnology research and promoting evidence-based practices. The event will include informative talks from young as well as experienced scientists from the three countries.
The event will also include keynote lectures, plenary sessions, oral and poster presentations, discussions and other educational and social events that stimulate several networking opportunities among the young participants of Pakistan, Turkey and Kazakhstan.
The official highlighted that the forum aims to facilitate interactions within the young research community to discuss the latest developments in this rapidly advancing field and find ways to respond to the increasing demands of professionals and communities across the world.
This youth forum is planned to be a hybrid event depending on the preference of the participants in their submitted registration forms.
The topics to be covered during the forum include Genome editing and new breeding technologies, large-scale genomics and genomic selection in crop and livestock breeding, speed breeding for rapid genetic gain, variants of Cas proteins and their potential applications and high throughput phenomics.
Go here to see the original:
Pak-Turk-Kazakh Youth Forum on Biotech to be held in Sept - The Nation
Taipei, Taiwan, 23rdJune 2022 /SciadNewswire/BRIM Biotechnology, Inc.(BRIM, TWSE 6995) enters OTC trading in Taiwan on 23rdJune 2022, CST. The news was announced at the companys first earnings call on 22ndJune 2022.
Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM applies world-leading expertise in translational science to accelerate the development of early research technology platforms to clinical drug candidates. BRIM is led by Chairwoman and CEO Dr. Haishan Jang, and the companys current paid-in capital is approximately 23 million USD.
BRIM has several novel drug products in its pipeline, all underpinned by the companys proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform.
BRIMs lead candidate BRM421 has the potential to be a first-in-class peptide treatment for Dry Eye Syndrome (DES). Phase II/III clinical trials completed in the U.S. demonstrate that the drug has the potential to speed up the repair of corneal damage through stimulation of corneal stem cell proliferation and differentiation, as well as to treat disease symptoms. Data demonstrate that BRM421 is safe and well-tolerated with a unique early onset curative effect1.
In only seven years, BRIM has progressed BRM421 from pre-clinical to late-stage clinical trials and has successfully licensed the commercial rights in greater China (China, Hong Kong, and Macau) to Grand Pharma (China) Co., Ltd (HK00512). The rapid development and significant licensing deals reflect the unique advantage of the PDSP technology platform and BRIMs expertise.
Dr. Jang commented, Our goal is restoration and repair of the damage caused by DES. The PDSP technology platform underpinning BRM421 and other assets in our pipeline could revolutionize the ophthalmology and degenerative joint disease fields. If successful, BRM421 could treat millions of people around the world living with DES and provide an excellent example of a first-in-class new drug developed in Asia. OTC trading brings us one step closer to achieving our vision to bring sustainable and affordable healthcare innovation to the world.
DES is a common yet complex chronic disease. According to Global Data (2020)2, the DES market size in 2018 was approximately 3.9 billion USD across nine markets (US, France, Germany, Italy, Spain, UK, Japan, China, and India). This market is expected to grow in scale and size due to heavy screen-time usage, greater use of contact lenses and increasing numbers of eye surgeries3. Global Data predicts that the DES market size will reach approximately 11 billion USD in 20282. Research also suggests that COVID-19 increases the risk of developing DES4.
Currently, treatment options for DES are very limited and most treat the symptoms rather than the disease. Existing treatments include anti-inflammatories or artificial tears and lubricants, none of which repair the damage caused by DES.
Peptides shorter than 40 amino acids, such as BRM421, are categorized as small molecules, meaning they follow the New Drug Application (NDA) regulatory pathway rather than the Biologics License Application (BLA) pathway. This significantly reduces development time and costs, making novel peptides an attractive new treatment option for many pharmaceutical companies.
Beyond BRM421, BRIMs PDSP technology platform can be applied across multiple therapy areas and indications. Early research indicates that the PDSP technology platform demonstrates efficacy in corneal wound healing, diabetic ulcer wound healing, osteoarthritis, androgenic alopecia, and muscle/tendon regeneration. BRIM has a rapidly expanding pipeline which includes treatments for severe corneal damage (BRM423), and osteoarthritis (BRM521).
With this next step of OTC trading, we are excited to progress development at an accelerated pace and will continue our journey in ophthalmology to bring the first regenerative peptide therapy for DES to the market in the near future, as well as apply our learnings to a wide range of other diseases with significantly unmet needs, said Dr. Jang.
BRIM Biotechnology, Inc.Shih-Ya ChangT: 886 2 2659 8586 #111E:info@brimbiotech.com
Sciad CommunicationsMaria Patey / Sophie ProtheroeT: 020 3405 7892E:BrimBiotech@sciad.com
About BRIM Biotechnology, Inc.
BRIM Biotechnology, Inc. is a clinical-stage company developing novel regenerative therapies in ophthalmology and degenerative joint diseases. Established in July 2013 to accelerate the development and transformation of early research technology platforms to clinical drug candidates, BRIM applies world-leading expertise in translational science to develop new treatments that help combat and cure disease. The companys virtual business model, combined with its proprietary PDSP technology platform, bridges the gap between research and clinical development faster, de-risks the process, and accelerates the progression of early-stage candidates in indications with high unmet medical needs.
For more information, please visitwww.brimbiotech.com.
More here:
BRIM Biotechnology enters OTC trading in Taiwan - Bio-IT World
BOSTON--(BUSINESS WIRE)--The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the inaugural recipients of the 2022 Termeer Scholars Awards. These prestigious new awards support emerging biomedical researchers developing scientific advances like new medicines and diagnostics that represent the future of the biotechnology industry and the potential to positively impact patients lives.
This years co-recipients of the Termeer Scholars Award are Omar Abudayyeh and Jonathan Gootenberg, McGovern Institute Fellows at the Massachusetts Institute of Technology (MIT) whose lab is leveraging natural biological systems, including CRISPR biology, to develop a suite of tools for next-generation cellular engineering. These tools have been adopted by researchers over the world and formed the basis for four companies that Omar and Jonathan have co-founded. They will receive a $50,000 grant to support professional development, knowledge advancement and/or stakeholder engagement and will become part of The Termeer Foundations signature Network of Termeer Fellows (first-time CEOs and entrepreneurs) and Mentors (experienced industry leaders).
The Termeer Foundation is working to improve the long odds of biotechnology by identifying and supporting future biotech leaders; if we help them succeed as leaders, we can help their innovations reach patients. While our Termeer Fellows program has supported first time CEOs and entrepreneurs for the past five years, our new Termeer Scholars program will provide much needed support to the researchers whose innovative ideas represent the future of the biotechnology industry - researchers like Omar and Jonathan, said Alan Walts, Co-Founder and Member of the Board of Directors for The Termeer Foundation.
The Abudayyeh-Gootenberg lab at MIT is developing a suite of new tools to enable next-generation cellular engineering, with uses in basic research, therapeutics and diagnostics. Building off the revolutionary biology of natural biological systems, including mobile genetic elements and CRISPR systems, the team develops new approaches for understanding and manipulating genomes, transcriptomes and cellular fate. The technologies have broad applications, including in oncology, aging and genetic disease.
Omar Abudayyeh is a McGovern Institute Fellow at MIT. He was part of the Harvard-MIT Health Sciences and Technology program as an MD/PhD student and completed his doctoral work in Feng Zhangs lab at the Broad Institute, where his research centered on novel CRISPR enzymes for applications in genome editing, therapeutics, and diagnostics. Dr. Abudayyeh was recognized as a Technology Review TR35 Innovator, Endpoints 20 under 40 awardee, 2018 Forbes 30 under 30 in Science and Health Care, and Business Insider 30 under 30.
Jonathan Gootenberg is a McGovern Institute Fellow at MIT and received his PhD in Systems Biology from Harvard University, during which he conducted research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute. During his PhD, Gootenberg focused on the development of molecular technologies for treating and sensing disease states, crossing disciplines by utilizing novel computational techniques, microbiology, biochemistry, and molecular biology to uncover new CRISPR tools, including Cas12 and Cas13. He and his co-authors developed Cas13 into a toolbox with uses in fundamental research, therapeutics, and diagnostics. He has received multiple awards, including the Technology Review TR35, Forbes 30 Under 30, Endpoints 20 Under 40, and Business Insider 30 and Under.
"The Termeer Foundation is committed to championing emerging biotechnology leaders and finding people who want to solve the biggest problems in human health, said Belinda Termeer, President of The Termeer Foundation. "By supporting researchers like Omar and Jonathan, we plant the seeds for future success in individuals who are preparing to make significant contributions in academia and industry.
Abudayyeh and Gootenberg were honored at the Termeer Foundations annual dinner in Boston on June 16, 2022. The event also recognized the 2022 class of Termeer Fellows.
About The Termeer Foundation
Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundations network of emerging and established healthcare innovators cultivates tomorrows leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at http://www.termeerfoundation.org or on LinkedIn @TermeerFoundation.
Here is the original post:
The Termeer Foundation Selects Inaugural Termeer Scholars: CRISPR Pioneers and Biotechnology Innovators Omar Abudayyeh and Jonathan Gootenberg of MIT...
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. ( SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will present data from its hypoimmune platform at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.
About Sana BiotechnologySana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements about Sana Biotechnology, Inc. (the Company, we, us, or our) within the meaning of the federal securities laws, including those related to the companys vision, progress, and business plans, the Companys participation at the ISSCR Annual Meeting, and the subject matter of the Companys presentations and data being presented at ISSCR Annual Meeting. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Companys strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Companys current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk factors identified in the Companys SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 10, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:Nicole Keith[emailprotected][emailprotected]
LONDON--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) has been appointed to provide global custody, fund accounting, depositary services and its outsourced trading service Integrated Trading Solutions to International Biotechnology Trust and its investment manager SV Health Managers.
Founded in 1994, International Biotechnology Trust is a United Kingdom (UK) investment trust, that, as at end of May 2022, had a market capitalisation of over 255 million. Publicly-traded on the London Stock Exchange, its objective is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies with the potential for high growth through the development and/or commercialisation of a product, device or enabling technology.
Laurence Everitt, head of Global Fund Services, UK at Northern Trust said: We are delighted to partner with International Biotechnology Trust and SV Health Managers in delivering the administration, execution and technology capabilities they and their investors require. Our Whole Office approach to working with investment managers allows us to deliver these solutions via a single platform and integrated service model reducing business complexity for clients while helping us meet their evolving requirements.
Northern Trusts Global Fund Services business provides services including fund administration, global custody, investment operations outsourcing and data solutions to global investment managers supporting a range of complex investment strategies across the full spectrum of asset classes.
Integrated Trading Solutions is part of Northern Trust Capital Markets, which is comprised of a number of Northern Trust entities that provide trading and execution services on behalf of institutional clients, including institutional brokerage, foreign exchange, securities lending and transition management.
About Northern Trust
Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 22 U.S. states and Washington, D.C., and across 23 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2022, Northern Trust had assets under custody/administration of US$15.5 trillion, and assets under management of US$1.5 trillion. For more than 130 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Please visit our website or follow us on Twitter.
Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Please read our global and regulatory information.
Go here to read the rest:
Northern Trust Appointed to Provide Asset Servicing Solutions to International Biotechnology Trust - Business Wire
The Biotechnology Algae Cultivation Process (Micro Algae) Market researchexamines market estimates and predictions innicedetail. Itadditionallyaidswithin theexecutionof thosefindings by demonstrating tangiblebenefitsto business stakeholders andbusinessleaders.eachcompanyshouldanticipatehowevertheir productare going to beutilized inthe longer term. Giventhislevel of uncertainty caused by the COVID-19state of affairs, thisanalysisisessentialforhigherunderstanding previous disruptions and increasing readiness forsuccessivesteps in decision-making.the foremostrecent studymakes an attempttoaltertheadvancedmarketplace forcompanyexecutives by providing strategic insights and exhibiting resiliency insuddenconditions. The insightswillassist all potential readers indistinguishingnecessarybusinessbottlenecks.
The primary objective of the report is to educate business owners and assist them in making an astute investment in the market. The study highlights regional and sub-regional insights with corresponding factual and statistical analysis. The report includes first-hand, the latest data, which is obtained from the company website, annual reports, industry-recommended journals, and paid resources. The Biotechnology Algae Cultivation Process (Micro Algae) report will facilitate business owners to comprehend the current trend of the market and make profitable decisions.
Market Leaders Profiled:
Report Analysis & Segments:
The Biotechnology Algae Cultivation Process (Micro Algae) is segmented as per the type of product, application, and geography. All of the segments of the Biotechnology Algae Cultivation Process (Micro Algae) are carefully analyzed based on their market share, CAGR, value and volume growth, and other important factors. We have also provided Porters Five Forces and PESTLE analysis for a deeper study of the Biotechnology Algae Cultivation Process (Micro Algae).The report also constitutes recent development undertaken by key players in the market which includes new product launches, partnerships, mergers, acquisitions, and other latest developments.
Based on Product Type Biotechnology Algae Cultivation Process (Micro Algae) is segmented into
Based on the Application Biotechnology Algae Cultivation Process (Micro Algae) is segmented into
The report provides insights on the following pointers:
1 Market Penetration: Comprehensive information on the product portfolios of the top players in the Biotechnology Algae Cultivation Process (Micro Algae).
2 Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.
3 Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market.
4 Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
5 Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Biotechnology Algae Cultivation Process (Micro Algae).
Schedule a Consultation Call With Our Analysts / Industry Experts to Find a Solution For Your Business @ https://www.marketresearchintellect.com/ask-for-discount/?rid=375531
Various Analyses Covered:
Regional assessment of the Biotechnology Algae Cultivation Process (Micro Algae) has been carried out over six key regions which include North America, Asia-pacific, Europe, Latin America, Middle East, and Africa. Moreover, the report also delivers deep insights on the ongoing research & development activities, revenue, innovative services, the actual status of demand and supply, and pricing strategy. In addition to this, this report also delivers details on consumption figures, export/import supply, and gross margin by region. In short, this report provides a valuable source of guidance and clear direction for the marketer and the part interested in the market.
North America(United States, Canada)Asia Pacific(China, Japan, India, South Korea, Australia, Indonesia, Others)Europe(Germany, France, United Kingdom, Italy, Spain, Russia, Others)Latin America(Brazil, Mexico, Others) The Middle East and Africa
Frequently Asked Questions:
About Us:Market Research Intellect
Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.
Contact Us:Mr. Steven FernandesMarket Research IntellectNew Jersey (USA)Tel: +1-650-781-4080
Email:sales@marketresearchintellect.com
What is biotechnology?
Biotechnology is the use of biology to develop new products, methods and organisms intended to improve human health and society. Biotechnology, often referred to as biotech, has existed since the beginning of civilization with the domestication of plants, animals and the discovery of fermentation.
Early applications of biotech led to the development of products such as bread and vaccines. However, the discipline has evolved significantly over the last century in ways that manipulate the genetic structures and biomolecular processes of living organisms. The modern practice of biotechnology draws from various disciplines of science and technology, including the following:
This approach has resulted in innovations and breakthroughs in the following areas:
Modern applications of biotechnology work most often through genetic engineering, which is also known as recombinant DNA technology. Genetic engineering works by modifying or interacting with the genetic cell structures. Every cell in an animal or plant contains genes that produce proteins. It's those proteins that determine the characteristics of the organism.
By modifying or interacting with genes, scientists can strengthen the characteristics of an organism or create an entirely new organism. These modified and new organisms may be beneficial to humans, such as crops with higher yields or increased resistance to drought. Genetic engineering also enables the genetic modification and cloning of animals, two controversial developments.
Biotechnology began at least 6,000 years ago with the agricultural revolution. This early era was characterized by exploiting living organisms in their natural forms or modifying their genetic makeup through selective breeding.
Around the same time, humans learned to harness the biological process of fermentation to produce bread, alcohol and cheese. People also began changing the genetic makeup of domesticated plants and animals through selective breeding.
Selective breeding works by breeding parents with desirable characteristics to express or eliminate certain genetic characteristics in their offspring. Over time, species that are selectively bred evolve to be different from their wild ancestors. For instance, during the agricultural revolution, wheat was selectively bred to stay on its stem when harvested instead of falling to the ground like wild wheat. Dogs were selectively bred to be more docile than their wolf ancestors.
However, biotech methods such as selective breeding can take a long time to show changes in species. Biotechnology remained limited to these slow, agricultural methods until the 19th century when biologist Gregor Mendel discovered the basic principles of heredity and genetics.
Also, during that era, scientists Louis Pasteur and Joseph Lister discovered the microbial processes of fermentation. This laid the foundation for biotechnology industries where scientists interact more directly with the molecular and genetic processes of organisms.
Based on the work of these scientists, genetic engineering was developed in 1973. This method is the foundation of modern biotechnology practices and recent advances. It enabled the first direct manipulation of plant and animal genomes, which is the complete set of genes present in a cell.
Over the last 100 hundred years or so, biotechnology emerged with the following discoveries and advancements:
1919. Hungarian scientist Karl Ereky coins the term biotechnology.
1928. Alexander Fleming discovers penicillin, the first true antibiotic.
1943. Oswald Avery proves DNA carries genetic information.
1953. James Watson and Francis Crick discover the double helix structure of DNA.
1960s. Insulin is synthesized to fight diabetes, and vaccines for measles, mumps and rubella are developed.
1969. The first synthesis of an enzyme in vitro, or outside the body, is conducted.
1973. Herbert Boyer and Stanley Cohen develop genetic engineering with the first insertion of DNA from one bacteria into another.
1980s. The first biotech drugs to treat cancer are developed.
1890. The United States Supreme Court rules that a "live human-made microorganism is patentable subject matter," meaning GMOs can be intellectual property.
1982. A biotech-developed form of insulin becomes the first genetically engineered product approved by the U.S. Food and Drug Administration (FDA).
1983. The first genetically modified plant is introduced.
1993. GMOs are introduced into agriculture with the FDA approval of growth hormones that produce more milk in cows.
1997. The first mammal is cloned.
1998. The first draft of the Human Genome Project is created, giving scientists access to over 30,000 human genes and facilitating research on treatment of diseases such as cancer and Alzheimer's.
2010. The first synthetic cell is created.
2013. The first bionic eye is created.
2020. MRNA vaccine and monoclonal antibody technology is used to treat the SARS-CoV-2 virus.
The science of biotechnology is broken down into subdisciplines that are color-coded based on common uses and applications.
The use and commercialization of modern biotechnology often fall into four main fields: environment, medicine, industry and agriculture.
The aim of environmental biotechnology is to develop sustainable environmental practices that reduce pollution and waste. The following are examples of environmental biotech:
Medical biotechnology, also known as biopharma, aims to fight and prevent disease and improve healthcare. Biotechnology and biomedical research are the basis of the modern pharmaceutical industry. Uses include the following:
Industrial biotechnology involves using microorganisms to produce industrial goods. Examples include the following:
Agricultural biotechnology genetically engineers plants and animals to produce more efficient agriculture, increase nutritional value and reduce food insecurity. Some examples of agricultural biotechnology are the following:
Biotechnology production offers a variety of advantages and solutions to critical problems. The main ones are the following:
Biotechnology also comes with disadvantages and misuse. The main disadvantages include the following:
Concerns about biotechnology's disadvantages have led to efforts to enact legislation restricting or banning certain processes or programs, such as human cloning, GMOs and embryonic stem-cell research.
Biotechnology is critical to environmentally sound advancements in agriculture. Learn more about how technology like artificial intelligence (AI) is improving the food industry.
Original post:
What is Biotechnology? Definition, Types and Applications | TechTarget
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients with hormone receptor positive, HER2-negative, HER2-mutant metastatic breast cancer, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in person from June 3-7 in Chicago, IL, and online. The poster, entitled Neratinib + fulvestrant + trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): outcomes and biomarker analysis from the SUMMIT trial, was presented at the Breast Cancer -- Metastatic Poster Session (poster #1028) by Komal L. Jhaveri, MD, FACP, Medical Oncologist at Memorial Sloan Kettering Cancer Center on June 6 at 9:00 a.m. ET.
Earlier genomic analyses from a cohort treated with a combination of neratinib and fulvestrant suggest that resistance to neratinib may occur via mutant allele amplification or secondary HER2 mutations. The addition of trastuzumab to the combination of neratinib and fulvestrant in this trial demonstrated positive durable responses in patients with HR-positive, HER2-mutant MBC who had received prior CDK4/6 inhibitors (CDK4/6i).
The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that included a cohort evaluating the efficacy of the triplet combination of neratinib (N), plus fulvestrant (F), plus trastuzumab (T), in patients with HR-positive, HER2-negative, HER2-mutant metastatic breast cancer, as identified by local genomic sequencing, who had previously received CDK4/6 inhibitors. In order to confirm the contribution of neratinib to the combination, a small, randomized cohort comparing neratinib plus fulvestrant plus trastuzumab versus fulvestrant plus trastuzumab versus fulvestrant was also included. A range of HER2 allelic variants was represented in the cohort. Patients who received the triplet regimen were enrolled in the non-randomized cohort and received 240 mg of neratinib per day intramuscularly, 500 mg intravenous fulvestrant on days 1 and 15 of Cycle 1 and then every 4 weeks, 8mg/kg body weight trastuzumab initially and then 6mg/kg every 3 weeks. Patients in the randomized cohort received either a combination of neratinib, fulvestrant, and trastuzumab, or fulvestrant and trastuzumab, or fulvestrant alone in a 1:1:1 ratio. To counter the side effects of diarrhea, loperamide prophylaxis was mandatory for the first two treatment cycles. Patients who were randomized to the combination of fulvestrant and trastuzumab, or fulvestrant alone, could cross over to receive neratinib, fulvestrant, and trastuzumab at progression. Efficacy was assessed using objective response rate (ORR) and clinical benefit rate (CBR). Tumor tissue was retrospectively assessed by central next-generation sequencing (NGS).
The table below summarizes the efficacy of SUMMIT MBC patients who received neratinib plus fulvestrant plus trastuzumab, those who received fulvestrant plus trastuzumab, and those who received fulvestrant alone; and also those who received fulvestrant plus trastuzumab or fulvestrant and then crossed over to neratinib plus fulvestrant plus trastuzumab upon progression. Patients who received neratinib plus fulvestrant plus trastuzumab (non-randomized + randomized) had a 35.3% investigator-assessed objective response rate, 14.3-month duration of response, 41.7% clinical benefit rate, and 8.2-month median progression-free survival. Neratinib appears to be a critical component of the combination therapy, as demonstrated by lack of response in the small cohort of patients treated with fulvestrant or fulvestrant plus trastuzumab, and by response in a subset of those patients upon crossover to neratinib plus fulvestrant plus trastuzumab.
Table: Efficacy Findings from HR+ Metastatic Breast Cancer Patients
Non-randomized +
Randomized
After crossover
Randomized
After crossover
Randomized HR+
HR+
from F+T to
HR+
from F to N+F+T
Prior CDK4/6i
Prior CDK4/6i
N+F+T
Prior CDK4/6i
(N+F+T, n=51)
(F+T, n=7)
(n=4)
(F, n=7)
(n=6)
18 (35.3)
0
1 (25.0)
0
2 (33.3)
1 (2.0)
0
0
0
0
17 (33.3)
0
1 (25.0)
0
2 (33.3)
Best overall response*
25 (49.0)
0
1 (25.0)
0
2 (33.3)
14.3 (6.4NE)
No response
6.2 (NENE)
No response
6.3 (6.26.4)
24 (47.1)
0
1 (25.0)
0
5 (83.3)
8.2 (4.712.7)
3.9 (1.94.1)
8.25 (NENE)
4.1 (1.64.1)
NE
These results suggest that the combination of neratinib, fulvestrant, and trastuzumab together is promising for treating HR+ and HER2-mutated MBC with prior exposure to CDK4/6i across a range of HER2 mutations.
Dr. Jhaveri, an investigator of the trial, said, Patients with hormone receptor-positive, HER2-negative, HER2-mutant metastatic breast cancer who had received prior treatment with CDK4/6 inhibitors demonstrated encouraging clinical activity with durable responses when treated with the triplet combination of neratinib with fulvestrant and trastuzumab. These responses were observed in patients whose tumors harbored a wide spectrum of HER2 mutations, including those with co-occurring HER3 mutations, regardless of ductal or lobular histology, and with a range of HER2 protein expression.
Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers. We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.
Important Safety Information Regarding NERLYNX (neratinib) U.S. Indication
NERLYNX (neratinib) tablets, for oral use
INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS:
The most common adverse reactions (reported in 5% of patients) were as follows:
To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.
DRUG INTERACTIONS:
See the original post:
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting - Business Wire
Need for a more reliable, accurate and cost-efficient testing platform
VANCOUVER, BC, June 7, 2022 /PRNewswire/ - Microbiome Insights, Inc., a global leader for end-to-end microbiome sequencing and comprehensive bioinformatic analysis,announced today it was awarded an $881,000 contract from Health Canada to develop a testing platform to accurately identify and characterize micro-organisms found in microbial biotechnology products, and predict their interactions that could mask or enhance adverse effects to determine risks to human and environmental health. This contract follows an initial agreement completed in 2021 and is part of Innovative Solutions Canada, a competitive federal funding program for innovators and federal agencies to collaborate and further commercialize new technology.
"Leveraging our expertise in metagenomics and metatranscriptomics, we are excited to continue our collaboration with Health Canada to develop a testing platform that will benefit both regulators and the manufacturers of microbial mixture products," said Dr. Pedro Dimitriu, the Head of Research and Development at Microbiome Insights. "The translation of microbiome science into products is accelerating and with this, there is a real need for a more reliable, accurate and cost-efficient way to determine the quality and safety of these new products."
Products with microbial mixtures have the capacity to perform novel and complex tasks in a diverse array of biotechnology applications, many of which support the goals of sustainability. The testing required for regulatory approval of these products can be costly, often relying on animal testing to understand their toxicity. There are no suitable test methodologies and novel approaches to determine the adverse effects of microbial mixtures.
As part of the Innovative Solutions Canada program, Microbiome Insights is developing a more reliable, accurate, and cost-efficient way to determine the quality and safety of these new products.
About Microbiome Insights Inc.
Microbiome Insights, Inc. is a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatics analysis. The company is headquartered in Vancouver, Canada, where samples from around the world are processed in its College of American Pathologists (CAP) accredited laboratory. Working with clients from pharma, biotech, nutrition, cosmetic and agriculture companies, and world-leading academic and government research institutions, Microbiome Insights has supported over 700 microbiome studies, from basic research to commercial R&D and clinical trials. The company's expert bioinformaticians and data scientists deliver industry-leading insights, including biomarker discovery, machine-learning-based modelling and customized bioinformatics analysis.www.microbiomeinsights.com
Health Canada
Health Canada is the Federal department responsible for helping Canadians maintain and improve their health. It ensures that high-quality health services are accessible and works to reduce health risks. Health Canada is committed to improving the lives of all of Canada 's people and to making this country's population among the healthiest in the world as measured by longevity, lifestyle, and effective use of the public health care system.www.canada.ca/en/health-canada.html
Innovative Solutions Canada
Innovative Solutions Canada (ISC) is a competitive federal funding program for innovators and federal agencies to collaborate and further commercialize new technology. It is a key component of the Canadian government's Innovation and Skills Plan, a multi-year plan to make Canada a global innovation leader and prepare Canadians to succeed in tomorrow's economy. http://www.ic.gc.ca/eic/site/101.nsf/eng/home
SOURCE Microbiome Insights
Go here to read the rest:
Microbiome Insights awarded Innovative Solutions Canada contract by Health Canada to enhance regulatory testing for microbial biotechnology products -...
Ottawa, Canada & Pittsburgh, USA, July 12, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
The collaboration will combine the capabilities of Peptilogics AI platform (NautilusTM) with Orion Biotechnologys proprietary drug discovery platform. The companies will leverage expertise in peptide design and engineering to drive drug discovery against an undrugged peptidergic GPCR linked to highly prevalent, life-threatening diseases.
Peptilogics Nautilus platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom design therapeutics. Additionally, Peptilogics supercomputer accelerates model development and prediction and evaluation of peptide sequences, to produce higher-quality hits with greater chance of success. Synergistically, Orion Biotechnologys platform explores receptor-ligand shape space using proprietary multiplex synthesis technology to generate precision-engineered peptides with enhanced potency and tailored signaling activity. Orions platform generates data matrices for AI-assisted lead optimization, offering one of the fastest drug discovery and development solutions to target peptidergic GPCRs.
On the announcement of this collaboration, Dr. Oliver Hartley, VP Drug Discovery at Orion Biotechnology commented We are pleased to be partnering with Peptilogics to push the boundaries of receptor pharmacology and AI computing to accelerate innovation for improved patient outcomes. An AI-driven paradigm shift is happening in drug discovery, and Orion is pleased to be at the forefront of applying AI to the highly valuable space around GPCRs. The ideal fit between Orions platform and unique knowledge of receptor-ligand interactions with Peptilogics machine learning models will position us to make AI-driven GPCR drug discovery a reality.
Using Peptilogics Nautilus platform, we combine proprietary deep generative models, predictive models, and biophysical simulation to design multiparameter-optimized peptides that have the potential to address historically challenging and novel drug targets. Our AI algorithms enable efficient navigation of the vast peptide design space, allowing us to uncover molecules that may not be discovered through traditional screening, said Nicholas Nystrom, Ph.D., Chief Technology Officer of Peptilogics. We are excited to partner with Orion Biotechnology for their deep GPCR expertise. By combining the strengths of Peptilogics Nautilus AI-driven peptide design platform and Orions GPCR platform, we aim to reduce the risk, time, and cost for drug design.
About Orion Biotechnology
Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs). Orions world-renowned experts in GPCR pharmacology and peptide/protein engineering leverage Orions proprietary drug discovery platform to rapidly and efficiently advance a diversified portfolio of precision engineered GPCR-targeted therapeutic candidates for the treatment of cancer and other serious diseases. To learn more, follow the company on LinkedIn or visit https://orionbiotechnology.com/.
About Peptilogics
Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation. For more information about Peptilogics, visitwww.peptilogics.comor follow the company on Twitter and LinkedIn.
View original post here:
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target -...
The once-forbidden concept of gene editing for predator control is back on the table after two projects received Government funding.
Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.
Last month, the crown entity responsible for pest control, Predator Free 2050, announced investment of $6.7 million into research projects, including $2.25m to investigate whether recent overseas advances in producing mice of only one sex could be adapted for rats, and $200,000 to explore stoat breeding genetics, and whether that could be used for control.
In November, it announced $300,000 in funding towards research that could help eradicate possums by spreading genes that reduced fitness, resulting in gradual population decline.
He admitted pest control was not the area in which hed first expected to see progress; there were opportunities for medicine and climate resilience, too.
There was a gap between what was researched, and what was developed for commercial use.
We know that New Zealand is one of the best countries at generating knowledge, Peters said. But when it comes to developing that, and getting some return, were terrible.
This is an excerpt. Read the original post here